新型亚硝基脲糖衍生物RFCNU用于消化道肿瘤的I期和II期临床试验初步结果
[Preliminary results of phase I and II clinical trials of RFCNU, a new nitrosourea sugar derivative, in digestive tract tumours].
作者信息
Mathé G, Serrou B, Hayat M, De Vassal F, Misset J L, Schwarzenberg L, Machover D, Ribaud P, Belpomme D, Jasmin C, Musset M, Montero J L, Imbach J L
出版信息
Biomedicine. 1977 Nov;27(8):294-7.
RFCNU or (chloro-2-ethyl)-l-(ribofuranosyl-isopropylidene-2', 3' paranitrobenzoate-5')-3 nitrosourea, a new synthetic nitrosourea derivative, which has been shown to have, in mice, among all nitrosourea derivatives tested, the longest maximallly efficient dose interval (MEDI) and which is not immunosuppressive at the smallest dose of MEDI, gave in a phase II trial on digestive tract tumours (at the dose of 400 mg/m2 per month determined by the phase I trial), 30% objective remissions among which 13% were greater than 50%.
RFCNU即（氯-2-乙基）-1-（呋喃核糖基-异亚丙基-2',3'-对硝基苯甲酸酯-5'）-3-亚硝基脲，一种新的合成亚硝基脲衍生物，在小鼠身上的测试表明，在所有测试的亚硝基脲衍生物中，它具有最长的最大有效剂量间隔（MEDI），并且在最小的MEDI剂量下不会产生免疫抑制作用。在一项针对消化道肿瘤的II期试验中（采用I期试验确定的每月400mg/m²的剂量），其客观缓解率为30%，其中13%的缓解率大于50%。
Zotero 插件